Abbreviations
- ACT:
-
Adoptive cell transfer
- ALL:
-
Acute lymphoblastic leukemia
- CAR:
-
Chimeric antigen receptor
- CIMT:
-
Association for Cancer Immunotherapy
- CLL:
-
Chronic lymphocytic leukemia
- CSF-1R:
-
Colony stimulating factor 1 receptor
- CTL:
-
Cytotoxic T lymphocytes
- CTLA-4:
-
Cytotoxic T-lymphocyte-associated protein 4
- CTx:
-
Chemotherapy
- DC:
-
Dendritic cells
- EMA:
-
European Medicines Agency
- EORTC:
-
European Organization for Research and Treatment of Cancer
- FDA:
-
Food and Drug Administration
- GM-CSF:
-
Granulocyte macrophage colony-stimulation factor
- HLA:
-
Human leukocyte antigen
- HMGB-1:
-
High-mobility group box-1
- HNPCC:
-
Hereditary nonpolyposis colorectal cancer
- HPV:
-
Human papilloma virus
- HSCT:
-
Hematopoietic stem cell transplantation
- IDH1:
-
Isocitrate dehydrogenase 1
- IFN:
-
Interferon
- IHC:
-
Immuno-histochemistry
- IL:
-
Interleukin
- iNOS:
-
Inducible nitric oxide synthetase
- mAb:
-
Monoclonal antibody
- MDACC:
-
MD Anderson Cancer Center
- MDSC:
-
Myeloid-derived suppressor cells
- MEK:
-
MAP kinase kinase
- MHC:
-
Major histocompatibility complex
- MMP-2:
-
Matrix metalloproteinase-2
- MMR:
-
Mismatch repair
- MSI:
-
Microsatellite instability
- mTEC:
-
Medullary thymic epithelial cells
- NGS:
-
Next-generation sequencing
- NHL:
-
Non-Hodgkin lymphoma
- OS:
-
Overall survival
- OVA:
-
Ovalbumin
- PBMC:
-
Peripheral blood mononuclear cells
- PCR:
-
Polymerase chain reaction
- PD-1:
-
Programmed death-1
- PDAC:
-
Pancreatic ductal adenocarcinoma
- PFS:
-
Progression-free survival
- RIP:
-
Rat insulin promoter
- RNA:
-
Ribonucleic acid
- SLP:
-
Synthetic long peptide
- TAM:
-
Tumor-associated macrophages
- TCGA:
-
The Cancer Genome Atlas
- TCR:
-
T cell receptor
- Teff :
-
Effector T cell
- TGF:
-
Transforming growth factor
- TIL:
-
Tumor-infiltrating lymphocytes
- TLR:
-
Toll-like receptor
- TNF:
-
Tumor-necrosis factor
- Treg :
-
Regulatory T cells
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest. Björn-Philipp Kloke has been co-organizer of the CIMT Endeavour workshop.
Rights and permissions
About this article
Cite this article
Miller, M., Jahndel, V., Kutscher, S. et al. The right patient for the right therapy: 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 11–13, 2015. Cancer Immunol Immunother 65, 1277–1287 (2016). https://doi.org/10.1007/s00262-016-1850-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-016-1850-5